Deal Announcements

Juvaris Nets $6M in First Series A

Tuesday, January 09, 2007 7:30:00 AM PDT | VentureDeal Staff

PLEASANTON, CA -- Juvaris BioTherapeutics announced that it has closed its first series A round of $6 million.  The company expects to close another $6 million within 120 days, to bring the total series A to $12 million.

The company is developing an immunotherapeutic platform for the treatment of infectious diseases and cancers using lipid-DNA complexes.

The investment came from the Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund, which is a purpose-driven fund that focuses its investments on treatments or vaccines for pandemics.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1